An MR1-specific nanobody capable of blocking MR1T cell activation
Authors:
- Timothy A BatesTBTimothy A Bates
- Corinna A KulickeCKCorinna A Kulicke
- Sintayehu K GurmessaSGSintayehu K Gurmessa
- Se-Jin KimSKSe-Jin Kim
- Sushant SureshSSSushant Suresh
- Jules B Reyes-WeinsteinJRJules B Reyes-Weinstein
- Audrey HinchliffAHAudrey Hinchliff
- John E BurkeJBJohn E Burke
- David M LewinsohnDLDavid M Lewinsohn
- Fikadu G TafesseFTFikadu G Tafesse
- 7 June 2026
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 215 (6)
Abstract
MR1 is a non-polymorphic, ubiquitously expressed, MHC class I-like antigen-presenting molecule that presents small-molecule metabolites to T cells. Studies have shown that MR1 plays a role in microbial infection, inflammation, and tumor immunity. The antigens it presents include metabolites of microbial and self-origin as well as small-molecule drugs and form stable complexes with MR1 that are displayed on the cell surface to activate T cells. However, unlike classical MHC I and II molecules, the fundamental biology of MR1 remains poorly understood, particularly the mechanisms governing antigen loading and intracellular trafficking. This knowledge gap is largely due to the lack of molecular tools available to precisely manipulate MR1 function. In this study, we describe a high-affinity (1.6 nM KD) anti-MR1 nanobody, MR1Nb1. We characterize the binding of this nanobody including affinity by ELISA and kinetics by BLI. Crucially, we map the binding epitope of MR1Nb1 on MR1 by HDX-MS, providing key insights into the mechanism through which it blocks MR1T cell activation. In functional assays MR1Nb1 effectively and specifically blocks MR1T cell activation by cells infected with M. tuberculosis or treated with M. smegmatis supernatant or the synthetic ligand deazalumazine. MR1Nb1 further stains MR1-ligand complexes on the cell surface in a flow cytometry assay. This nanobody represents a unique and versatile tool for the field, as it can be produced inexpensively and expressed intracellularly within antigen presenting cells. Hence, our study provides a powerful new molecular probe for dissecting the mechanistic underpinnings of MR1 biology and uncover its broader roles in immunity.Keywords
Funding Information
- Natural Science and Engineering Research Council Discovery (NSERC-RGPIN-2026-04961)
- National Institutes of Health (R01AI141549)
- National Institutes of Health (T32AI170496)
- the Silver Innovation Award
- Merit Award (#I01 BX000533)
- U.S. Department of Veterans Affairs Biomedical Laboratory
- UVic-GBC Proteomics Centre
- Genome British Columbia (384PRO) and the CFI Innovation Fund (45877)
- U.S. Department of Veterans Affairs or the United States Government
This publication has 55 references indexed in Scilit:
- M13 Bacteriophage Display Framework That Allows Sortase-Mediated Modification of Surface-Accessible Phage ProteinsBioconjugate Chemistry, 2012
- Human Mucosal Associated Invariant T Cells Detect Bacterially Infected CellsPLOS Biology, 2010
- Antimicrobial activity of mucosal-associated invariant T cellsNature Immunology, 2010
- Immunodominant Tuberculosis CD8 Antigens Preferentially Restricted by HLA-BPLOS Pathogens, 2007
- Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs)Journal of Immunological Methods, 2007
- Evidence for MR1 Antigen Presentation to Mucosal-associated Invariant T CellsJournal of Biological Chemistry, 2005
- Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1Nature, 2003
- A Gene Outside the Human MHC Related to Classical HLA Class I GenesScience, 1995
- A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharksNature, 1995
- Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chainsNucleic Acids Research, 1991